Core Viewpoint - 基石药业-B's stock price increased by 3.09% to 7.01 HKD, with a trading volume of 37.03 million HKD, following the announcement of key clinical data to be presented at the upcoming ESMO annual meeting in 2025 [1] Group 1: Clinical Pipeline Updates - 基石药业's core clinical pipeline includes CS2009, a PD-1/VEGF/CTLA-4 tri-specific antibody, and CS5001, an ROR1 antibody-drug conjugate (ADC) [1] - The I期 dose-escalation clinical data summary for CS2009 has been published on the ESMO website, covering data from 9 patients as of May 8, 2025 [1] - At the ESMO conference, 基石药业 will present preliminary data from the I期 dose-escalation study of CS2009 involving approximately 70 patients with advanced solid tumors, marking the first known clinical data publication globally for a PD-1/VEGF/CTLA-4 tri-specific antibody [1]
基石药业-B现涨超3% 将于ESMO大会上公布PD-1/VEGF/CTLA-4三抗I期剂量递增...